Helen M. R. Robinson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Helen M. R. Robinson has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Eeson Rajendra
MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK
55 shared publications - Graeme C. M. Smith
Artios Pharma, The Glenn Berge Building, Babraham Research Campus, Cambridge, UK
52 shared publications - Jayesh B. Majithiya
Artios Pharma, Cambridge, United Kingdom
52 shared publications - Marco Ranzani
Artios Pharma, Cambridge, United Kingdom
52 shared publications - Vera Grinkevich
Artios Pharma, Cambridge, United Kingdom
51 shared publications - Marie Boursier
Artios Pharma, Babraham Research Campus, Cambridge, UK
50 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data1 from The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
Supplementary data to support the main figures
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data1 from The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
Supplementary data to support the main figures
- Open Access
- 23 July 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (12) , 7233-7247
Deciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations
- 23 July 2026
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 53 (12) , 7233-7247
Open AccessDeciphering the phenotypic responses to 177Lu-based radioligand therapy to identify efficacious combinations
- Open Access
- 13 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (19) , 4489-4503
The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
Purpose: DNA polymerase theta (Polθ) is the central component of DNA double-strand break repair through microhomology-mediated end joining (MMEJ). Targeting Polθ for cancer therapy has been proposed due to its tumor-selective expression, as well as its role in the survival of homologous recombination–deficient (HRD) cancer cells. Additionally, inhibition of Polθ has been shown to potentiate the effects of DNA damage, such as that caused by poly (ADP-ribose) polymerase (PARP) inhibition. In this study, we present the pharmacologic profile of ART6043, a potent, selective, allosteric, small-molecule inhibitor of the polymerase function of Polθ. Experimental Design: A series of in vitro studies were performed to demonstrate the biochemical and cellular on-target activity of ART6043 in relevant model systems, focusing on combination with PARP inhibitors. Subsequent in vivo studies established a pharmacokinetic/pharmacodynamic/efficacy relationship and explored ART6043’s ability to potentiate the efficacy of PARP inhibitors across a range of cell line-derived xenograft (CDX), patient-derived xenograft (PDX), and genetically engineered mouse models of HRD tumors. Results: ART6043 inhibits Polθ with low nmol/L potency and specifically abrogates MMEJ in cells. Additionally, ART6043 inhibits the survival of HRD cells and potentiates the efficacy of PARP inhibitors in vitro. Furthermore, ART6043 has excellent pharmaceutical properties, is well tolerated, and induces tumor regressions in combination with PARP inhibitors in vivo in HRD models. Conclusions: The data demonstrate strong potential for ART6043 as an anticancer therapeutic for HRD tumors in combination with PARP inhibitors. Based on this, combination therapy of ART6043 with PARP inhibitor treatment is being tested in an ongoing phase I/IIa clinical trial (NCT05898399).
- 13 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (19) , 4489-4503
Open AccessThe Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy
Purpose: DNA polymerase theta (Polθ) is the central component of DNA double-strand break repair through microhomology-mediated end joining (MMEJ). Targeting Polθ for cancer therapy has been proposed due to its tumor-selective expression, as well as its role in the survival of homologous recombination–deficient (HRD) cancer cells. Additionally, inhibition of Polθ has been shown to potentiate the effects of DNA damage, such as that caused by poly (ADP-ribose) polymerase (PARP) inhibition. In this study, we present the pharmacologic profile of ART6043, a potent, selective, allosteric, small-molecule inhibitor of the polymerase function of Polθ. Experimental Design: A series of in vitro studies were performed to demonstrate the biochemical and cellular on-target activity of ART6043 in relevant model systems, focusing on combination with PARP inhibitors. Subsequent in vivo studies established a pharmacokinetic/pharmacodynamic/efficacy relationship and explored ART6043’s ability to potentiate the efficacy of PARP inhibitors across a range of cell line-derived xenograft (CDX), patient-derived xenograft (PDX), and genetically engineered mouse models of HRD tumors. Results: ART6043 inhibits Polθ with low nmol/L potency and specifically abrogates MMEJ in cells. Additionally, ART6043 inhibits the survival of HRD cells and potentiates the efficacy of PARP inhibitors in vitro. Furthermore, ART6043 has excellent pharmaceutical properties, is well tolerated, and induces tumor regressions in combination with PARP inhibitors in vivo in HRD models. Conclusions: The data demonstrate strong potential for ART6043 as an anticancer therapeutic for HRD tumors in combination with PARP inhibitors. Based on this, combination therapy of ART6043 with PARP inhibitor treatment is being tested in an ongoing phase I/IIa clinical trial (NCT05898399).
- Open Access
- 12 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (24) , eaeb4508
SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy
Inhibition of DNA polymerase theta (Polθ), an essential enzyme for repairing DNA double-strand breaks (DSBs) via microhomology-mediated end joining (MMEJ), has proven to be an exquisitely effective monotherapy in HR-deficient tumor models. In addition, Polθ inhibition (Polθi) can induce tumor-selective radiosensitization, but unlike its monotherapy use, no clinically actionable biomarkers have yet been identified to predict this effect. Here, we profiled 54 cancer cell lines and found that Polθi induces substantial radiosensitization in most models, although with marked variability not explained by indicators of Polθ activity. To pinpoint molecular determinants of radiosensitization by Polθi, we performed a CRISPR knockout screen which revealed loss of the TP53BP1/Shieldin pathway component SHLD2 ( FAM35A ) as a vulnerability to Polθi combined with RT. We found that SHLD2 is deleted in a subset of human prostate cancers, frequently alongside PTEN loss, an adverse prognostic factor. We demonstrated that SHLD2 loss not only increases sensitivity to RT alone, as reported previously, but also enhances the radiosensitizing effect of Polθi, independently of PTEN status and without requiring HR deficiency. Moreover, our findings support a model in which SHLD2 deficiency increases Polθ dependence following RT, with Polθ activity limiting DSB accumulation and chromosomal instability, via a compensatory mechanism independent of canonical MRE11/CtIP-mediated DNA end resection. In summary, we found that SHLD2 loss is a collateral vulnerability that can be exploited through combined treatment with Polθi and RT.
- 12 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (24) , eaeb4508
Open AccessSHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy
Inhibition of DNA polymerase theta (Polθ), an essential enzyme for repairing DNA double-strand breaks (DSBs) via microhomology-mediated end joining (MMEJ), has proven to be an exquisitely effective monotherapy in HR-deficient tumor models. In addition, Polθ inhibition (Polθi) can induce tumor-selective radiosensitization, but unlike its monotherapy use, no clinically actionable biomarkers have yet been identified to predict this effect. Here, we profiled 54 cancer cell lines and found that Polθi induces substantial radiosensitization in most models, although with marked variability not explained by indicators of Polθ activity. To pinpoint molecular determinants of radiosensitization by Polθi, we performed a CRISPR knockout screen which revealed loss of the TP53BP1/Shieldin pathway component SHLD2 ( FAM35A ) as a vulnerability to Polθi combined with RT. We found that SHLD2 is deleted in a subset of human prostate cancers, frequently alongside PTEN loss, an adverse prognostic factor. We demonstrated that SHLD2 loss not only increases sensitivity to RT alone, as reported previously, but also enhances the radiosensitizing effect of Polθi, independently of PTEN status and without requiring HR deficiency. Moreover, our findings support a model in which SHLD2 deficiency increases Polθ dependence following RT, with Polθ activity limiting DSB accumulation and chromosomal instability, via a compensatory mechanism independent of canonical MRE11/CtIP-mediated DNA end resection. In summary, we found that SHLD2 loss is a collateral vulnerability that can be exploited through combined treatment with Polθi and RT.
- Open Access
- 26 November 2025
- Vol. 53 (22)
Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy.
Flap endonuclease 1 (FEN1) is a structure-specific nuclease with critical functions in DNA replication and repair. FEN1 has been proposed as an anti-cancer drug target because of its synthetic lethal interaction with homologous recombination deficiency (HRD). However, the exploration of FEN1 in this context has been hampered by the lack of suitable small molecule tools. Here, we describe MSC778, a highly potent, specific and selective small molecule inhibitor of FEN1 nuclease activity. MSC778 directly engages FEN1 in cells, enhances its retention on chromatin, and selectively kills BRCA-deficient cells. Mechanistically, MSC778 suppresses DNA replication causing S-phase accumulation, DNA damage, and ultimately, cell death. Cancer cell panel screening identified Ewing sarcoma (EWS) cells as sensitive to MSC778, which is driven by the expression of SLFN11. In addition to HRD, CRISPR screening revealed a spectrum of synthetic lethal interactions between MSC778 and DNA damage response (DDR) factors, such as PARP1, USP1, PARG, and ATR. Furthermore, we demonstrate that combined inhibition of these factors with MSC778 induces synergistic killing of cancer cells. Together these data highlight FEN1 inhibition as an attractive precision oncology strategy either as monotherapy or as a combination therapy with a broad range of current and next generation DDR-targeting agents.
- 26 November 2025
- Vol. 53 (22)
Open AccessMechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy.
Flap endonuclease 1 (FEN1) is a structure-specific nuclease with critical functions in DNA replication and repair. FEN1 has been proposed as an anti-cancer drug target because of its synthetic lethal interaction with homologous recombination deficiency (HRD). However, the exploration of FEN1 in this context has been hampered by the lack of suitable small molecule tools. Here, we describe MSC778, a highly potent, specific and selective small molecule inhibitor of FEN1 nuclease activity. MSC778 directly engages FEN1 in cells, enhances its retention on chromatin, and selectively kills BRCA-deficient cells. Mechanistically, MSC778 suppresses DNA replication causing S-phase accumulation, DNA damage, and ultimately, cell death. Cancer cell panel screening identified Ewing sarcoma (EWS) cells as sensitive to MSC778, which is driven by the expression of SLFN11. In addition to HRD, CRISPR screening revealed a spectrum of synthetic lethal interactions between MSC778 and DNA damage response (DDR) factors, such as PARP1, USP1, PARG, and ATR. Furthermore, we demonstrate that combined inhibition of these factors with MSC778 induces synergistic killing of cancer cells. Together these data highlight FEN1 inhibition as an attractive precision oncology strategy either as monotherapy or as a combination therapy with a broad range of current and next generation DDR-targeting agents.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
ART558 treatment leads to increased residual IR-induced DNA damage foci. A, γH2AX and 53BP1 foci in HCT116 and H460 cells treated with 3 μmol/L ART558 and 4 Gy IR, assessed at the indicated times points after IR. B, Representative images from irradiated cells from the experiment described in A, at 16 hours after IR. C, Micronuclei in HCT116 and H460 cells treated with 3 μmol/L ART558 and 4 Gy IR, assessed 48 hours after IR. Data points indicate the mean ± SD from triplicate wells and graphs are representative from three separate experiments. D, Representative images from irradiated cells from the experiment described in C. Micronuclei are indicated with arrow heads. dsDNA, double-stranded DNA. E, RAD51 foci in HCT116 and H460 cells treated with 3 μmol/L ART558 and 4 Gy IR, assessed 6 hours after IR. F, Representative images from irradiated cells from the experiment described in E. Lines and error bars in A and E correspond to average ± SD representative from three independent experiments, and statistical significance was calculated using nonparametric one-way ANOVA (Kruskal–Wallis) with Dunn correction for multiple comparisons (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
ART558 treatment leads to increased residual IR-induced DNA damage foci. A, γH2AX and 53BP1 foci in HCT116 and H460 cells treated with 3 μmol/L ART558 and 4 Gy IR, assessed at the indicated times points after IR. B, Representative images from irradiated cells from the experiment described in A, at 16 hours after IR. C, Micronuclei in HCT116 and H460 cells treated with 3 μmol/L ART558 and 4 Gy IR, assessed 48 hours after IR. Data points indicate the mean ± SD from triplicate wells and graphs are representative from three separate experiments. D, Representative images from irradiated cells from the experiment described in C. Micronuclei are indicated with arrow heads. dsDNA, double-stranded DNA. E, RAD51 foci in HCT116 and H460 cells treated with 3 μmol/L ART558 and 4 Gy IR, assessed 6 hours after IR. F, Representative images from irradiated cells from the experiment described in E. Lines and error bars in A and E correspond to average ± SD representative from three independent experiments, and statistical significance was calculated using nonparametric one-way ANOVA (Kruskal–Wallis) with Dunn correction for multiple comparisons (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Cell cycle-dependent effects of ART558 in combination with IR
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Cell cycle-dependent effects of ART558 in combination with IR
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Distribution of POLQ mRNA levels across cell lines from CCLE
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Distribution of POLQ mRNA levels across cell lines from CCLE
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Accompanies Figure 4 (Characterization of ART899 as a specific and potent Polθ inhibitor with improved stability)
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Accompanies Figure 4 (Characterization of ART899 as a specific and potent Polθ inhibitor with improved stability)
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Polθ inhibitor ART899 combined with radiation causes significant tumor growth delay in vivo and is well tolerated. A, ART899 plasma concentration following oral dosage of ART899 at 50 or 150 mg/kg. Mouse plasma samples (n = 3 per treatment group) were collected at 30 minutes, 1, 2, 4, 8, and 12 hours after last dose. B–E, HCT116 tumor-bearing mice treated with 150 mg/kg Polθ inhibitor ART899 twice daily for 12 days and/or 10 × 2 Gy (days 1–5 and 8–12). Vehicle (n = 9); ART899 (n = 10); 10 × 2 Gy + vehicle (n = 10); 10 × 2 Gy + ART899 (n = 10). B, Mean ± SEM relative tumor size. P value from mixed effect model and Dunnett post-test. Comparison of tumor size at the latest common timepoint for 10 × 2 Gy versus 10 × 2 Gy + ART899 are shown in Supplementary Fig. S6A. C, Individual mouse graphs. D, Kaplan–Meier plot for a tumor size threshold of 1,000 mm3. HR: Hazard ratio (hazard rate of IR arm / hazard rate of IR + ART899 arm); P value from the log-rank (Mantel-Cox) test comparing IR alone and IR + ART558. The median time to a tumor size of 1,000 mm3 for the IR + ART899 arm versus the IR arm and the corresponding ratio are shown in Supplementary Fig. S6B. E, Average mouse weight ± SD from all treatment groups over time. Individual mouse weights are shown in Supplementary Fig. S6C.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Polθ inhibitor ART899 combined with radiation causes significant tumor growth delay in vivo and is well tolerated. A, ART899 plasma concentration following oral dosage of ART899 at 50 or 150 mg/kg. Mouse plasma samples (n = 3 per treatment group) were collected at 30 minutes, 1, 2, 4, 8, and 12 hours after last dose. B–E, HCT116 tumor-bearing mice treated with 150 mg/kg Polθ inhibitor ART899 twice daily for 12 days and/or 10 × 2 Gy (days 1–5 and 8–12). Vehicle (n = 9); ART899 (n = 10); 10 × 2 Gy + vehicle (n = 10); 10 × 2 Gy + ART899 (n = 10). B, Mean ± SEM relative tumor size. P value from mixed effect model and Dunnett post-test. Comparison of tumor size at the latest common timepoint for 10 × 2 Gy versus 10 × 2 Gy + ART899 are shown in Supplementary Fig. S6A. C, Individual mouse graphs. D, Kaplan–Meier plot for a tumor size threshold of 1,000 mm3. HR: Hazard ratio (hazard rate of IR arm / hazard rate of IR + ART899 arm); P value from the log-rank (Mantel-Cox) test comparing IR alone and IR + ART558. The median time to a tumor size of 1,000 mm3 for the IR + ART899 arm versus the IR arm and the corresponding ratio are shown in Supplementary Fig. S6B. E, Average mouse weight ± SD from all treatment groups over time. Individual mouse weights are shown in Supplementary Fig. S6C.